ClinicalTrials.gg
Active, not recruitingNCT05046821INSPIRE-IBMUpdated May 27, 2026

Sporadic Inclusion Body Myositis Natural History Study

An observational study in Sporadic Inclusion Body Myositis and Inclusion Body Myositis, sponsored by University of California, Irvine. Active, not recruiting at 13 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by University of California, Irvine · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
150
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Myositis, Inclusion Body with a site in United States — 4 open to participants now, 9 under way, 2 of them phase 3. Myositis, Inclusion Body · United States.

Enrollment
4th of 10
150 · median 59
Started
2021
the only one that year
Observational
10 of 37
3 open now
Registered
30th of 37
by date

Among the 37 studies in Myositis, Inclusion Body with a site in United States, this one is the 4th largest by enrollment of the 10 observational ones that give a count, is the only one that started in 2021, is one of 10 observational ones, and was the 30th registered.

Myositis, Inclusion Body

65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.

Browse Myositis, Inclusion Body studies →

Open to participants now

4 of the 37 studies in Myositis, Inclusion Body with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Myositis, Inclusion Body studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Myositis, Inclusion Body with a site in United States, or all of them as a file.
02

Study summary

This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants, enrolled across 13 sites, with sporadic IBM, diagnosed according to established criteria.

Read the detailed description

This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants with sporadic IBM, diagnosed according to established criteria. Participants will require an routine serum sample via blood draw to evaluate for NT5c1A antibody status. This testing will be performed at Washington University School of Medicine in the Neuromuscular Laboratory. Investigators will be blinded to antibody status. A subset of participants (40) will undergo a muscle biopsy at the Baseline visit.

Aim 1. To determine for the first time whether NT5c1A antibodies mediate disease progression over a two-year interval in patients with sIBM.

We will perform a prospective, non-interventional, observational study on patients with sIBM with follow up and evaluations every 6 months over a two-year time frame. Primary analyses are: 1) the rates of disease progression and severity as measured by rates of decline in IBM Functional Rating Scale (IBMFRS) score and Timed Get Up and Go (TUG); 2) the presence or absence of serum antibodies to NT5c1A; and 3) the presence and frequency of variant T-cells in the serum and skeletal muscle.

Aim 2. To perform a detailed morphological, histochemical and immunohistochemical analysis of fresh muscle biopsy specimens obtained from a subset of patients with sIBM.

Aim 3. To characterize the distribution of "immunosenescent" lymphocytes in circulating blood from patients with sIBM.

Aim 4. To quantify the decline in the respiratory function of sIBM patients.

03

Conditions studied

  • Sporadic Inclusion Body Myositis
  • Inclusion Body Myositis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Paticipants age 40 and older with sporadic IBM, diagnosed according to established criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages 40 years and older
  2. Fulfills ENMC 2011 criteria of clinically definite or probable sporadic Inclusion body myositis (sIBM)
  3. Disease onset is within the past 10 years of the time of Baseline visit
  4. Able to participate and comply with study related procedures
  5. Able to provide written consent

Exclusion criteria

Exclusion Criteria:

  1. Current or very recent use (within last 6 months of the Baseline visit) of immunomodulation or therapy.
  2. Current or very recent use (within last 90 days of the Baseline visit) of an medication or therapy.
  3. Co-existing significant medical or surgical conditions that, in the opinion of the investigator, will influence study participation or alter natural history.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
150 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Inclusion Body Myositis Functional Rating Scale (IBMFRS)

    The IBMFRS is a 10 item questionnaire. Scores for each item range from 0 to 4. There is a total maximum score of 40 and minimum score of 0. The higher the score the better functional status of the person.

    Time frame: Change from Baseline to Month 24

  2. Timed Up and Go (TUG)

    Stand up from a chair, walk 3 meters, sit back down in chair

    Time frame: Change from Baseline to Month 24

  3. Frequency of immunophenotypic abnormalities in blood and muscle

    Laboratory assessment

    Time frame: Change from Baseline to Month 24

  4. Forced Vital Capacity (FVC) (sitting)

    breathing test

    Time frame: Change from Baseline to Month 24

Secondary outcomes

  1. Manual Muscle Testing

    muscle strength testing

    Time frame: Change from Baseline to Month 24

  2. Hand Held Dynamometry

    muscle strength testing

    Time frame: Change from Baseline to Month 24

  3. Sydney Swallow Questionnaire

    swallow ability questionnaire

    Time frame: Change from Baseline to Month 24

  4. EAT-10 Questionnaire

    swallow ability questionnaire

    Time frame: Change from Baseline to Month 24

  5. NIH PROMIS questionnaires

    quality of life questionnaires

    Time frame: Change from Baseline to Month 24

  6. Forced Vital Capacity (supine)

    breathing test done while lying down

    Time frame: Change from Baseline to Month 24

  7. Maximum Inspiratory Pressure/Maximum Expiratory Pressure

    breathing tests

    Time frame: Change from Baseline to Month 24

  8. sporadic inclusion body myositis physical functioning assessment (sIFA)

    functional ability questionnaire

    Time frame: Change from Baseline to Month 24

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Mar 2027, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2021
First posted
Sep 16, 2021
StartActual
Oct 11, 2021
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05046821
Responsible party
Tahseen Mozaffar (Professor of Neurology, University of California, Irvine) — Principal investigator
First posted
Sep 16, 2021
Start date
Oct 11, 2021
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
May 27, 2026

Study contacts

Tahseen Mozaffar, MD FAAN, FANA
principal investigator · University of California, Irvine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion